Holen Sie sich die Stockscreener-App
1.29
1.57%
0.02
Handel nachbörslich:
1.29
Opko Health Inc Aktie (OPK) Neueste Nachrichten
Here's why you should retain OPK stock in your portfolio for now - MSN
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Health stock (US68375N1037): earnings update keeps focus on pipeline and Rayaldee outlook - AD HOC NEWS
OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN
OPKO Health stock (US68375N1037): Company updates keep the biotech name in focus - AD HOC NEWS
Opko Health, Inc.Common Stock (NQ: OPK - FinancialContent
OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity - AD HOC NEWS
ModeX to present preclinical CAR-T data at gene therapy meeting - Investing.com UK
OPKO Health’s ModeX Therapeutics Will Present Data - GlobeNewswire
Spotlight On Promising Penny Stocks For May 2026 - simplywall.st
OPK.O| Stock Price & Latest News - Reuters
Here's why you should hold OPK stock in your portfolio for now - msn.com
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
MSN Money - MSN
OPK Stock Price, Quote & Chart | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill
OPKO Health, Inc. (NASDAQ:OPK) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat
OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com
OPKO gains 15% stake in Nicoya for China RAYALDEE rights - Investing.com UK
[ARS] OPKO HEALTH, INC. SEC Filing - Stock Titan
Board structure and pay detailed in OPKO Health (NASDAQ: OPK) 2026 proxy - Stock Titan
OPKO gains 15% stake in Nicoya for China RAYALDEE rights By Investing.com - Investing.com South Africa
OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - marketscreener.com
Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat
Order lab tests online or at home: BioReference opens new platform - Stock Titan
BioReference Launches BioReference Direct, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform - Moomoo
OPKO Health (OPK) reports Q1 loss, misses revenue estimates - MSN
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - sharewise.com
OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo
OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat
This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia
OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat
H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com
OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga
OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... By GuruFocus - Investing.com Canada
OPKO Health Q1 2026 Earnings Call Transcript - MarketBeat
OPKO Health Q1 Earnings Call Highlights - MarketBeat
OPK: Clinical pipeline advances and operational improvements drive improved Q1 2026 results - TradingView
1.19%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):